Sun and MedImmune settle Ethyol patent litigation
This article was originally published in Scrip
Executive Summary
Sun Pharmaceutical Industries and its subsidiaries have signed an agreement with MedImmune Oncology, ending all patent litigation between them concerning Sun's US ANDA for a generic version of MedImmune's Ethyol (amifostine for injection 500mg).